The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative 131I dose over 37 GBq

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2265|83|1|117-123

ISSN： 0300-0664

Source： CLINICAL ENDOCRINOLOGY, Vol.83, Iss.1, 2015-07, pp. : 117-123

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic administration of 131I for differentiated thyroid cancer, radiation dose to ovaries and outcome of

By Garsi J. P.   Schlumberger M.   Rubino C.   Ricard M.   Labbé M.   Ceccarelli C.   Schvartz C.   Henri-Amar H.   Bardet S.   De Vathaire F.  

Radioprotection, Vol. 43, Iss. 5, 2008-09 ,pp. : 039-039

Edp Sciences

Access to resources Recommend Favorite

Clinical applications of SPECT/CT after first I‐131 ablation in patients with differentiated thyroid cancer

By  

CLINICAL ENDOCRINOLOGY, Vol. 81, Iss. 3, 2014-09 ,pp. : 445-451

John Wiley & Sons Inc

Access to resources Recommend Favorite

The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma

By Hänscheid H   Lassmann M   Buck A K   Reiners C   Verburg F A  

Physics in Medicine and Biology, Vol. 59, Iss. 10, 2014-05 ,pp. : 2353-2368

IOP Publishing

Access to resources Recommend Favorite

Scoring Patients’ Risk in Differentiated Thyroid Cancer

By  

Oncology Research and Treatment, Vol. 24, Iss. 6, 2002-01 ,pp. : 561-568

Karger

Access to resources Recommend Favorite

GONADAL EFFECT OF RADIATION FROM 131 I IN MALE PATIENTS WITH THYROID CARCINOMA

By Krassas G. E.   Pontikides N.  

Archives of Andrology, Vol. 51, Iss. 3, 2005-04 ,pp. : 171-175

Informa Healthcare

Access to resources Recommend Favorite